New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
17:05 EDTABIO, MDTARCA Biopharma plans new Phase 3 trial for Gencaro
ARCA Biopharma (ABIO) provided an update on a proposed, genetically-targeted clinical trial in atrial fibrillation of the company's lead developmental drug, Gencaro. The company also announced that Medtronic (MDT) has signed a non-binding Letter of Intent to collaborate on the initial, Phase 2B portion of the proposed trial.
News For ABIO;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
11:02 EDTMDTMedtronic begins enrollment in feasibility study of Valiant Mona LSA system
Medtronic announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery. Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday. He serves as the study's national primary investigator and receives consulting fees and honoraria for teaching from Medtronic. The study aims to enroll 24 subjects at up to seven sites in the United States. The purpose of the study is to characterize the safety and effectiveness of the investigational device acutely and at 30 days.
April 17, 2015
07:10 EDTMDTMedtronic's Solitaire improved neurological outcomes in stroke patients in trial
Subscribe for More Information
April 14, 2015
11:04 EDTMDTMedtronic to develop stent graft system under patent agreement with Sanford
Subscribe for More Information
09:16 EDTMDTMedtronic announces CE Mark for Micra TPS
Subscribe for More Information
April 13, 2015
17:13 EDTMDTIBM Medtronic to partner to improve diabetes care
IBM (IBM) and Medtronic (MDT) announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.
17:10 EDTMDTIBM establishes a Watson Health Cloud
Subscribe for More Information
08:33 EDTABIOARCA Biopharma receives FDA fast track designation for Gencaro AF development
ARCA biopharma announced that the U.S. Food and Drug Administration has designated as a Fast Track development program the investigation of Gencaro for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population. Gencaro is the company’s investigational, pharmacologically unique beta-blocker and mild vasodilator. Gencaro is currently being evaluated as a potential treatment for atrial fibrillation in a genetically-defined heart failure population in GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. ARCA anticipates that enrollment of approximately 200 patients in the Phase 2B portion of the trial will be completed by the end of 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use